PALI:NASDAQ, Palisade Bio, Inc.

PALI stock overview

Palisade Bio, Inc. (PALI:NASDAQ) closed at $1.12 on November 13, 2026, down 1.75% on the day. The stock trades 60.8% below its 52-week high of $2.86 and 3.7% above its 52-week low of $1.08. Over the past year, it lost 47.7%. Palisade Bio, Inc. is part of the Health Care sector.

Key figures

Price
$1.12
Day change
-1.75%
Volume
1,458,544
Average volume
3,064,393
Market cap
201M+
52-week range
$1.08 – $2.86
50-day average
$1.48
200-day average
$1.82

Price action over the past year

In 252 trading sessions since November 13, 2025, PALI closed higher on 110 days (44%). Its best day was June 29, 2026 (+17.99%) and its worst was April 22, 2026 (-16.43%). The stock moved 10% or more in a single session 18 times. It opened at least 5% above the previous day's high 2 times.

Recent signals

PALI news

About Palisade Bio, Inc.

Palisade Bio Inc is a late-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.

Similar stocks

Find more stocks like PALI with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.